Sign In
Buy OCUP
$1.17
+0 (+0%)
At Close: Jan 22, 2025
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
07:14am, Monday, 01'st Apr 2024
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
08:00am, Friday, 08'th Mar 2024
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule th
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
03:20pm, Monday, 26'th Feb 2024
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
08:00am, Friday, 23'rd Feb 2024
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commer
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Thursday, 15'th Feb 2024
FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-m
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
08:00am, Wednesday, 14'th Feb 2024
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A.
3 Value Stocks to Buy on the Dip: February 2024
12:47pm, Wednesday, 07'th Feb 2024
With the U.S. economy running at full steam and the labor market continuing to impress onlookers, the concept of value stocks might not be the most popular idea. After all, many of the usual suspects
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
08:00am, Monday, 05'th Feb 2024
FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-m
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Wednesday, 24'th Jan 2024
FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-m
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
09:01am, Thursday, 11'th Jan 2024
Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.
Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024 Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024
Ocuphire Pharma, Inc. (OCUP) Ocuphire Pharma Corporate Update Call (Transcript)
01:30pm, Tuesday, 05'th Dec 2023
Ocuphire Pharma, Inc. (NASDAQ:OCUP ) Corporate Update Call December 5, 2023 10:00 AM ET Company Participants Dr. George Magrath - Chief Executive Officer Michael Wood - LifeSci Advisors Charlie Hoffma
Bears are Losing Control Over Ocuphire Pharma, Inc. (OCUP), Here's Why It's a 'Buy' Now
11:16am, Thursday, 30'th Nov 2023
Ocuphire Pharma, Inc. (OCUP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions co
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
08:00am, Thursday, 30'th Nov 2023
Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023 Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
07:30am, Thursday, 30'th Nov 2023
After a rocky couple of years, there finally seems to be some light at the end of the tunnel for growth stocks. Interest rates have stabilized, and the economy is again showing signs of strength.
